卡前列素氨丁三醇致大面积红斑1例及文献分析

Large-Area Erythema Induced by Carboprost Tromethamine:A Case Report and Literature Analysis

目的为临床安全使用卡前列素氨丁三醇注射液提供参考。方法回顾性分析潍坊市妇幼保健院收治的1例肌肉注射卡前列素氨丁三醇注射液致注射部位大面积(26 cm×25 cm)红斑药品不良反应(ADR)的案例,并结合文献分析其发生原因。结果患者出现的注射部位大面积红斑与使用卡前列素氨丁三醇的因果关系为“很可能相关”(Naranjo量表评分为8分)。文献显示,该ADR可能与药品因素(辅料苯甲醇及成分氨丁三醇)、给药方式(肌肉注射)及个体差异[高龄(>30岁)、肥胖(体质量>70 kg)、顺产]等有关。结论该ADR属该药新的ADR,临床应加强用药安全监测及风险识别,保障患者安全用药。

Objective To provide a reference for the safe use of Carboprost Tromethamine Injection in clinical practice.Methods The treatment process of a case of large-area erythema(26 cm×25 cm)at the administration site induced by intramuscular injection of Carboprost Tromethamine Injection admitted to the Weifang Maternal and Child Health Care Hospital was analyzed retrospectively.The causes of this adverse drug reaction(ADR)were explored based on literature analysis.Results The causal relationship between the occurrence of large-area erythema at the injection site and the use of carboprost tromethamine was"probable"(the score of Naranjo's ADR evaluation scale was eight points).Literature showed that this ADR might be related to the drug factors[benzyl alcohol(excipient)and tromethamine(main component)],administration method(intramuscular injection)and individual differences[advanced age(>30 years),obesity(body weight>70 kg),spontaneous delivery)].Conclusion Large-area erythema is a new ADR of Carboprost Tromethamine Injection.Medication safety monitoring and risk identification should be strengthened in clinical practice to ensure the safe drug use for patients.